Navigation Links
Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
Date:10/4/2010

oring activating KRAS mutations, PFS was significantly inferior in the Vectibix arm. For patients with mutant KRAS tumors, median PFS was 7.3 months with Vectibix in combination with FOLFOX versus 8.8 months with FOLFOX alone (hazard ratio 1.29; 95 percent CI: 1.04-1.62; p=0.02).
  • These data confirm previous findings when oxaliplatin-based chemotherapy and an anti-EGFR antibody were combined in patients bearing tumors with activating KRAS mutations.
  • The response rate of Vectibix plus chemotherapy was higher than chemotherapy alone in the wild-type KRAS patient population as measured by blinded central review (55 percent versus 48 percent in the FOLFOX only arm).
  • Tumor KRAS status was ascertained in 93 percent of the 1,183 patients enrolled in the PRIME '203' trial, the highest number ever prospectively reported for a first-line trial.

  • "The outcome of this high quality trial demonstrated that Vectibix, which was administered every two weeks, improved progression-free survival as a first-line metastatic colorectal cancer treatment in a selected patient population," said Jean Yves-Douillard, M.D., Ph.D., director Clinical and Translational Research, Medical Oncology Branch, Centre R Gauducheau, France and PRIME '203' trial lead investigator and study author.

    '181' Results in Second-Line mCRC Demonstrate Vectibix Combined with Chemotherapy (FOLFIRI) Helped Patients with Wild-type KRAS mCRC Live Longer Without their Disease Worsening (PFS)

  • Results of the '181' trial showed that the addition of Vectibix to FOLFIRI (an irinotecan-based chemotherapy) significantly improved PFS (co-primary endpoint) (median 5.9 months for Vectibix plus FOLFIRI versus 3.9 months for patients treated with FOLFIRI alone, hazard ratio 0.73; 95 percent CI: 0.59-0.90; p=0.004) in the second-line treatment of patients with wild-type KRAS mCRC.
  • Although numerically great
    '/>"/>

  • SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
    2. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
    3. Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial
    4. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
    5. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
    6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
    7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
    8. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
    9. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
    10. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
    11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/29/2015)... 29, 2015 In recent years, the biopharmaceutical ... Big Data that can generate valuable insights. Despite this, ... Big Data have caused the biopharmaceutical sector to embrace ... According to a recent study by benchmarking ... a Big Data team or function in place; however, ...
    (Date:5/29/2015)... 2015 Market Publishers Ltd and ... a partnership agreement for quality market research promotion ... and sell research reports worked out by Chem-Report. ... commented upon the agreement: “Chem-Report is a Chinese ... and chemical markets on global and country levels. ...
    (Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/7bf7ff/cytogenetics ... new report "Cytogenetics - Technologies, Markets and ... report deals with cytogenetics in a broader sense ... the chromosome structure and identify abnormalities related to ... is also referred to as molecular cytogenetics. The ...
    (Date:5/28/2015)... DUBLIN , May 28, 2015 /PRNewswire/ ... ) has announced the addition of Jain ... Drugs, Markets and Companies"  to their offering.  ... ,Alzheimer,s disease remains a challenge in management. ... condition in the seven major markets of ...
    Breaking Biology Technology:New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
    ... Merge Healthcare (Nasdaq: MRGE ; TSX: MRG), today,announced ... NASDAQ,Listing Qualifications Panel stating that the panel determined to ... NASDAQ Stock Market,subject to the Company,s filing of its ... no later than January 29, 2008. As indicated in ...
    ... Development for the Conversion of Biomass to Bio-oil, ... November 1, Khosla Ventures and BIOeCON announce today ... Ventures, will provide the Series A,funding, whereas BIOeCON ... ,Biomass Catalytic Cracking Process, (BCC). KiOR Inc. will ...
    ... 1 A new technology known as,ActivePure ... proven in peer-reviewed, published university laboratory studies ... inoculated,surfaces. Recent outbreaks of MRSA in ... parents concerned. Based on NASA research, ...
    Cached Biology Technology:NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance 2NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance 3Khosla Ventures and BIOeCON Form KiOR Inc. 2Khosla Ventures and BIOeCON Form KiOR Inc. 3New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus (MRSA) 2
    (Date:5/26/2015)... DUBLIN , May 26, 2015 ... has announced the addition of the "Saudi ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Saudi Arabia is projected to grow ... This high growth is attributed to the surging ...
    (Date:5/22/2015)... According to a new market research report ... by Software (Middleware, Databases), by Hardware (Cameras, Integrated Devices), ... - Global Forecast to 2020", published by MarketsandMarkets, Facial ... to $6.19 Billion by 2020, at a CAGR of ... and   43 Figures spread through 140 Pages and ...
    (Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
    Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
    ... federal support for high-risk, high-reward research and development ... concludes a new white paper released today by ... Wilson International Center for Scholars. Innovative funding models ... and Space Administration and the Army offer blueprints ...
    ... Sciences Research Board has funded Washington Universitys International ... nearly $3 million for biofuels research. Researchers ... Louis University, the University of Missouri campuses in ... Plant Science Center. The emphasis of the ...
    ... new study published in the February 2008 print edition of ... that should reduce the cost and increase the availability of ... Pennsylvania researchers describe how they used gene therapy to reduce ... producing therapeutic proteins in their milk, such as insulin or ...
    Cached Biology News:How will government spur technological innovation in the 21st century? 2Missouri board grants Washington University Sustainability Center $3 million 2Pharmaceutical breakthrough may make a range of drugs cheaper and more available 2
    ... recombinant human angiogenin expressed in ... Physical form: Lyophilized from a ... phosphate buffered saline. Titertest ... Titertest values: capture ELISA ...
    CKB Antibody (N-term) Antigen: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected within aa 1~100 of human CKB. Molecular Weight: 42644 Da...
    ...
    The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
    Biology Products: